Sarepta Therapeutics Inc
SRPT
查看详细走势图
18.500USD
+1.470+8.63%
收盘 02/06, 16:00（美东）报价延迟15分钟
1.94B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+8.63%
5天
-9.05%
1月
-21.14%
6月
+3.01%
今年开始到现在
-14.03%
1年
-83.46%
查看详细走势图
TradingKey Sarepta Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Sarepta Therapeutics Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名89/159位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价30.32。中期看，股价处于平稳状态。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Sarepta Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Sarepta Therapeutics Inc亮点
亮点风险
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
业绩高增长
公司营业收入稳步增长，连续3年增长103.85%
业绩转盈
公司业绩转盈，最新年度盈利美元
估值合理
公司最新PE估值-6.85，处于3年历史合理位
机构减仓
最新机构持股90.74M股，环比减少17.69%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值854.00
活跃度降低
近期活跃度降低，过去20天平均换手率2.36
分析师目标
根据
27
位分析师
持有
评级
30.319
目标均价
+53.67%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Sarepta Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Sarepta Therapeutics Inc简介
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
公司代码SRPT
公司Sarepta Therapeutics Inc
CEOIngram (Douglas S)
网址https://www.sarepta.com/
相关品种
